Why the study?
Does losartan improve recovery of cardiac function and metabolism after ischemia-reperfusion in isolated rat hearts?
Does losartan improve recovery of cardiac function and metabolism after ischemia-reperfusion in isolated rat hearts?
Losartan protects the heart against acute ischemia-reperfusion injury through an unexpectedly bradykinin-dependent mechanism.
Answers are grounded in this paper and cite their sources.
Indicates bradykinin-dependent protection by losartan in rat hearts; leaves open clinical translation and human mechanism confirmation.
It is unclear whether losartan, an angiotensin II type 1 (AT1) receptor antagonist, protects the heart against acute ischemia-reperfusion injury. Therefore we evaluated cardiac protection conferred by pre- and postischemic treatment as well as by exclusive postischemic treatment with losartan. Furthermore, we sought to determine both the extent of this protection and its dependence on bradykinin in comparison with quinaprilat, a cardioprotective angiotensin-converting enzyme inhibitor. Cardiac protection was assessed as recovery of coronary flow, left ventricular developed pressure, phosphocreatine, and adenosine triphosphate (ATP) in isolated perfused rat hearts after 15 min of global ischemia and 30 min of postischemic reperfusion. We found that, in hearts pre- and postischemically treated with losartan (1 microM) or quinaprilat (0.1 microM), these variables all recovered significantly better than those in untreated control hearts. In hearts that were only postischemically treated with losartan, these variables also recovered significantly better than those in control hearts. In contrast, in hearts treated with the combination of the bradykinin B2 receptor antagonist Hoe 140 with quinaprilat or losartan, the recovery of the variables no longer differed from that in control hearts. In conclusion, losartan protects the heart against acute ischemia-reperfusion injury. This protection can be achieved by pre- and postischemic treatment as well as by exclusive postischemic treatment with losartan. Furthermore, the extent of this protection is equivalent to that conferred by quinaprilat and, unexpectedly, dependent on bradykinin.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: